The study is for subjects 18 and older. The study duration is up to 3 years. Subject will receive both oral study drug once daily and subcutaneous study drug every other week. Period 1 is 56 weeks and 13 site visits. Subject will have a site visit at week 56 and every 12 weeks thereafter.
The research study is available for participants 18 and older. The subject will take the study drug once daily. There are 13 office visits in Period 1. The study duration is up to 3 years. Subject will have a study visit at week 56 and every 12 weeks thereafter.
Rheumatoid Arthritis Prevention
Clinvest Research is currently enrolling participants for a phase 3 clinical study investigating a new selective JAK1 inhibitor for Rheumatoid Arthritis. Participants need to be over 18 years of age, have diagnosis of Rheumatoid Arthritis, have had an inadequate response or intolerant to previous treatments, and on a stable dose of a Synthetic Disease Modifying Anti-Rheumatic Drug. The study is up to 5 years in duration. Compensation for time and travel may be provided and study related care is at no cost.
Chronic Migraine Prevention
Clinvest Research is currently studying an investigational CGRP antibody (Eptinezumab) for the prevention of chronic migraines. Qualified participants between the ages 18-65 who have greater than 8 migraines and 15 headache days a month will receive two doses of study drug 12 weeks apart. The study is approximately 36 weeks long and has 10 office visits. Compensation for time and travel may be provided and study related care is at no cost. Call 417-883-7889 to learn more, or apply now at clinvest.com/chronic011.APPLY NOW
Episodic Migraine Study
DFN-15-CD-007: Efficacy, Tolerability, and Safety Study of DFN-15
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura.APPLY NOW
Migraine: Acute Treatment
UBR-MD-01: Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.APPLY NOW
Episodic Migraine Prevention
CGP-MD-01: Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention
This study will evaluate the safety and tolerability of the following doses of AGN-241689: 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.APPLY NOW
Alzheimer's Disease Study
LLCF: A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia (NAVIGATE-AD)
The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer’s disease (AD) dementia.APPLY NOW